Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis typ 2 diabetes mellitus~* Male and female on diet and exercise regimen, pre-treated with metformin 12 weeks prior to randomisation~* HbA1c equal or greater than 7.0% and less than or equal to 10% at visit 1~* 18 years or more~* BMI equal or less than 45Kg/m2~Exclusion criteria:~* Uncontrolled hyperglycemia defined as glucose more that 13.3 mmol/L after overnight fast during placebo run-in~* Any other antidiabetic drug within 12 weeks prior to randomisation except metformin~* Acute coronary syndrome (non-STEMI, STEMI unstable angina pectoris), stroke or transient ischemic attack within 12 weeks of informed consent~* Indication of liver disease~* Moderate to severe renal impairment~* Bariatric surgery within past 2 years~* Medical history of cancer or treatment for cancer within last 5 years~* Blood dyscrasias or any disorders causing haemolysis or unstable red blood cell~* Contraindications hypersensitivity to concomitant drugs~* Treatment with anti-obesity drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 10773 dose plus metformin (Type: EXPERIMENTAL): Patients receive one BI10773 tablet and one placebo Glimepiride capsule once daily
- Glimepiride 1-4 mg plus metformin (Type: ACTIVE_COMPARATOR): Patients receive one glimepiride capsule and one placebo tablet Bi 10773 once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).